La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

60 Degrees Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 5/6

60 Degrees Pharmaceuticals ha un patrimonio netto totale di $3.0M e un debito totale di $157.4K, che porta il suo rapporto debito/patrimonio netto a 5.3%. Le sue attività totali e le sue passività totali sono rispettivamente $4.3M e $1.4M.

Informazioni chiave

5.3%

Rapporto debito/patrimonio netto

US$157.44k

Debito

Indice di copertura degli interessi	n/a
Contanti	US$1.58m
Patrimonio netto	US$2.96m
Totale passività	US$1.37m
Totale attività	US$4.33m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $3.8M ) di SXTP superano le sue passività a breve termine ( $1.2M ).

Passività a lungo termine: Le attività a breve termine di SXTP ( $3.8M ) superano le sue passività a lungo termine ( $148.7K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SXTP ha più liquidità del suo debito totale.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di SXTP si sia ridotto negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SXTP ha una cash runway sufficiente per 3 mesi in base all'ultimo flusso di cassa libero riportato, ma da allora ha raccolto capitale aggiuntivo.

Previsione Cash Runway: Si prevede che SXTP disponga di liquidità sufficiente per 2 mesi in base alle stime del flusso di cassa libero, ma da allora ha raccolto capitale aggiuntivo.

60 Degrees Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

60 Degrees Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces 1:12 Reverse Stock Split to Bring the Company into Compliance with the Nasdaq's $1.00 Minimum Bid Price Requirement for Maintaining its Nasdaq Listing

60 Degrees Pharmaceuticals Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

60 Degrees Pharmaceuticals, Inc. announced delayed 10-Q filing

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Recent updates

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$4.68 loss

60 Degrees Pharmaceuticals, Inc. Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals Announces 1:12 Reverse Stock Split to Bring the Company into Compliance with the Nasdaq's $1.00 Minimum Bid Price Requirement for Maintaining its Nasdaq Listing

New major risk - Share price stability

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia Microti Despite Prior Treatment

60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center

60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients

Consensus revenue estimates fall by 13%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

High number of new and inexperienced directors

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.4001 million.

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.400101 million.

60 Degrees Pharmaceuticals, Inc. Plans Pivotal Babesiosis Study with Tafenoquine

60 Degrees Pharmaceuticals, Inc. Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

60 Degrees Pharmaceuticals, Inc. announced delayed 10-Q filing

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

60 Degrees Pharmaceuticals, Inc.'s Subsidiary 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Second quarter 2023 earnings released

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

60 Degrees Pharmaceuticals, Inc. Registers ACLR8-LR

New major risk - Market cap size

High number of new and inexperienced directors

60 Degrees Pharmaceuticals Receives Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane